Any perinatal death after randomisation · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in perinatal mortality (after randomisation) compared with fetal growth (low certainty).
1 finding from 1 review
Neonatal mortality · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in neonatal death compared with fetal growth (low certainty).
1 finding from 1 review
Preterm birth less than 28 weeks · women with twin pregnancies were randomised from 25 weeks
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gestational age at birth (weeks) · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in gestational age at birth (weeks) compared with fetal growth (moderate certainty).
1 finding from 1 review
Caesarean section · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in caesarean section (any) compared with fetal growth (high certainty).
1 finding from 1 review
Induction of labour · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in induction of labour compared with fetal growth (moderate certainty).
1 finding from 1 review
Number of antenatal hospital admissions · women with twin pregnancies were randomised from 25 weeks
Fetal growth (biometry) + umbilical artery Doppler showed no clear difference in antenatal admission to hospital compared with fetal growth (high certainty).
1 finding from 1 review
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of chronic GVHD · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
1 finding from 1 review
Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
1 finding from 1 review
Fetal/neonatal/infant · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid showed no clear difference in A1: Fetal or neonatal or infant death (< 1 year of age) – all… compared with single course (moderate certainty).
1 finding from 1 review
Respiratory distress syndrome · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid leads to lower A5: Respiratory distress syndrome – all fetuses randomised compared with single course (high certainty).
1 finding from 1 review
A7: Severe lung disease – all fetuses randomised · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid probably leads to lower A7: Severe lung disease – all fetuses randomised compared with single course (moderate certainty).
1 finding from 1 review
Chronic lung disease · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid showed no clear difference in A8: Chronic lung disease – all fetuses randomised compared with single course (high certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · the fetus/neonate/infant
Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroid showed no clear difference in A9: Severe intraventricular haemorrhage (grade 3 or 4) – all fetuses… compared with single course (moderate certainty).
1 finding from 1 review